Gland B2B Business Model and Growth Strategy
Business Overview
15
Extensive and Vertically Integrated Manufacturing Capabilities With Consistent Compliance Track Record
4 Finished
7 Facilities
Formulation Facilities
&
767 million units
3 API Facilities
11,000 kg/year and
R&D Pilot Plant
3 API facilities provide in-house
manufacturing capabilities for
critical APIs, thereby
Dundigal, Hyderabad
Sterile Injectables Facility
(Flagship)
API Facility
Pashamylaram, Hyderabad
Sterile Injectables Facility
Penems Facility
Consistent Compliance Track Record
⚫ No USFDA warnings letters since inception of each facility
⚫ Certified as GMP compliant at all manufacturing facilities by the
USFDA
⚫ Certain facilities certified by the MHRA (UK), ANVISA (Brazil),
AGES (Austria), TGA (Australia) and BGV Hamburg (Germany)
Note: (1) As of March 31, 2021.
Vishakhapatnam
Oncology Facility
2 API Facilities
°
Controlling costs and quality, and
•
Mitigating supply chain related
risks around key product
Quality Assurance and Quality Control
•
•
•
Team of 1,191 full-time employees, 30.07% of total employees (1)
Regular quality management reviews
35+ audits per year on average, including customer audits and
regulatory agency audits
GMP certifications for facilities
GLANDView entire presentation